4D Molecular Therapeutics (FDMT) Interest & Investment Income (2020 - 2026)
4D Molecular Therapeutics' (FDMT) quarterly Interest & Investment Income came in at $4.9 million in Q1 2026, down 12.86% year-on-year from $5.6 million in Q1 2025, and up 3.4% on a QoQ basis from $4.7 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Interest & Investment Income (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of Interest & Investment Income data on file, last reported at $4.9 million in Q1 2026.
- On a quarterly basis, Interest & Investment Income fell 12.86% year-over-year to $4.9 million in Q1 2026; TTM through Mar 2026 was $13.9 million, a 27.42% decrease from a year earlier, with the FY2025 full-year figure at $19.5 million, down 28.0% from the prior year.
- Interest & Investment Income for Q1 2026 stood at $4.9 million, up from $4.7 million in the prior quarter.
- Over the last five years, Interest & Investment Income for FDMT reached as high as $7.3 million in Q3 2024 and fell as low as -$998000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $2.6 million across 5 years, with a median of $1.3 million in 2022.
- Across the five-year window, Interest & Investment Income slumped 14357.14% in 2022 and soared 4565.6% in 2025, its largest moves.
- Year by year, Interest & Investment Income stood at $1.3 million in 2022, then jumped by 227.35% to $4.4 million in 2023, then surged by 47.65% to $6.5 million in 2024, then slipped by 27.26% to $4.7 million in 2025, then rose by 3.4% to $4.9 million in 2026.
- Per Business Quant data, the three most recent Interest & Investment Income figures were $4.9 million in Q1 2026, $4.7 million in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 44.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 19.51 Mn |
| 10 | 4D Molecular Therapeutics | 691.54 Mn | 300.64 Mn | - | 4.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.86 Mn |
| Dec 31, 2025 | 4.70 Mn |
| Sep 30, 2025 | 4.33 Mn |
| Jun 30, 2025 | 5,000.00 |
| Mar 31, 2025 | 5.58 Mn |
| Dec 31, 2024 | 6.47 Mn |
| Sep 30, 2024 | 7.29 Mn |
| Jun 30, 2024 | -184,000.00 |
| Mar 31, 2024 | -125,000.00 |
| Dec 31, 2023 | 4.38 Mn |
| Sep 30, 2023 | 3.88 Mn |
| Jun 30, 2023 | 615,000.00 |
| Mar 31, 2023 | 926,000.00 |
| Dec 31, 2022 | 1.34 Mn |
| Sep 30, 2022 | 795,000.00 |
| Jun 30, 2022 | -406,000.00 |
| Mar 31, 2022 | -998,000.00 |
| Dec 31, 2021 | -312,000.00 |
| Sep 30, 2021 | 435,000.00 |
| Jun 30, 2021 | 7,000.00 |